Search
ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly
She describes how the first trials will target glioma, a type of brain cancer, and Siren has also done work to show that the approach could be a universal therapy that may have utility against numerous cancers. Plus, how Siren did a unique crowdfunded $5 million fundraise. Coverage brought to you by
May 13
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors...
Apr 16, 2025
SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now
She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising...
Jan 16, 2025
UCSF's Nicole Paulk discusses AAV as a gene therapy vector
UCSF's Nicole Paulk discusses AAV as a gene therapy vector at Advanced Therapies Week in Miami Beach.
Jan 18, 2023
.png){kind=logo}